BLISS GVS PHARMA LTD.

24th May, 2016

To,
National Stock Exchange Ltd
Plot no. C/1 G Block,
Bandra-Kurla Complex,
BKC Road, Bandra (E),
Mumbai -400051

SUBJECT: BOARD MEETING OUTCOME

Dear Sir,

We like to inform you that the Board Meeting of the Company was held today i.e. on Tuesday, 24th May, 2016 at the registered office of the company at 3.30 p.m. The Board has considered and approved the following:

1. Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2016.

2. Auditors' Report on the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2016.

3. Form A (for audit report with un-modified opinion) for Standalone and Consolidated Financial for the year ended 31st March, 2016

4. Declared Final dividend at the rate of 50% i.e. Re. 0.50 per share.

5. Pursuant to section 188 of the Companies Act, 2013 approved the appointment of Mr. Vishal Rao and the reappointment of Mr. Gagan Sharma and Mr. Arjun Ashra in the managerial capacity.

6. Reappointment of Statutory Auditor of the Company.

7. Reappointment of Internal Auditor of the Company for the F.Y. 2016-17.

8. Reappointment of Secretarial Auditor for the F.Y. 2016-17.

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771
Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

9. Accepted the resignation of Mr. Hira Sadhak an Independent Director with effect from 17.05.2016.

10. Appointed of Mr. Santosh Parab as an Independent Director with effect from 24.05.2016.

Kindly acknowledged and take on record the same.

Thanking You,

For **BLISS GVS PHARMA LIMITED**

BLISS GVS PHARMA LTD. MUMBAI

VIPUL B. THAKKAR
CHIEF FINANCIAL OFFICER

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

BLISS GVS PHARMA LIMITED

Regd Office.102, Hyde Park, Sakivihar Road,
Andheri (East), Mumbai - 400 072

STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER AND YEAR ENDED 31.03.2016

PART - I

(Rs. In Lacs)

SR. NO.	PARTICULARS	STANDALONE					CONSOLIDATED	
		QUARTER ENDED			YEAR ENDED		YEAR ENDED	
		31.03.2016 (AUDITED)	31.12.2015 (UNAUDITED)	31.03.2015 (UNAUDITED)	31.03.2016 (AUDITED)	31.03.2015 (AUDITED)	31.03.2016 (AUDITED)	31.03.2015 (AUDITED)
1	**INCOME FROM OPERATIONS**							
	(a) NET SALES (NET OF EXCISE DUTY)	6092.27	8625.60	6796.32	31969.24	30945.89	53671.30	40307.34
	(b) OTHER OPERATING INCOME	468.01	61.08	68.51	669.11	356.28	1018.11	406.10
	TOTAL INCOME FROM OPERATIONS(NET)	**6560.28**	**8686.68**	**6864.83**	**32638.35**	**31302.17**	**54689.41**	**40713.44**
2	**EXPENSES**							
	a) CONSUMPTION OF RAW MATERIALS	3143.84	3147.08	2,946.33	13,490.28	13,784.13	25589.07	16456.36
	b) PURCHASE OF TRADED GOODS	0.00	0.00	0.00	36.37	90.32	508.76	933.42
	c) CHANGES IN INVENTORIES OF FINISHED GOODS ,WORK IN PROGRESS, STOCK IN	124.02	-80.18	113.10	-132.09	248.27	-421.30	364.87
	d) EMPLOYEE BENEFIT EXPENSES	562.60	579.64	469.38	2188.89	1736.08	3373.65	2942.90
	e) DEPRECIATION / AMORTISATION	143.92	148.44	145.07	585.24	507.83	1326.00	1129.62
	f) OTHER EXPENDITURE	1164.32	2469.76	2040.08	7445.08	6823.95	10108.90	9671.97
	TOTAL EXPENSES	**5138.70**	**6264.74**	**5713.96**	**23613.77**	**23190.58**	**40485.08**	**31499.14**
3	**PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COST & EXCEPTIONAL ITEMS (1-2)**	**1421.58**	**2421.94**	**1150.87**	**9024.58**	**8111.59**	**14204.33**	**9214.30**
4	OTHER INCOME	267.33	573.21	213.17	2307.57	2135.03	2435.00	2028.86
5	**PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COST (3+4)**	**1688.91**	**2995.15**	**1364.04**	**11332.15**	**10246.63**	**16639.33**	**11243.16**
6	FINANCE COST	305.13	298.43	296.42	1310.98	1121.18	1819.86	1641.24
7	**PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5-6)**	**1383.78**	**2696.72**	**1067.62**	**10021.17**	**9125.45**	**14819.47**	**9601.92**
8	EXCEPTIONAL ITEMS		-				-	
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7 - 8)	1383.78	2696.72	1067.62	10021.17	9125.45	14819.47	9601.92
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	915.71	559.80	421.51	3459.70	3123.90	4804.91	3462.58
11	NET PROFIT AFTER TAX FOR THE PERIOD (9 - 10)	468.07	2136.92	646.11	6561.47	6001.55	10014.56	6139.34
12	MINORITY INTEREST						-1766.30	-148.37
13	NET PROFIT AFTER TAX & MINORITY INTEREST (11-12)	468.07	2136.92	646.11	6561.47	6001.55	8248.26	5990.97
14	PAID - UP EQUITY CAPITAL	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)				42175.96	35787.14	40230.77	32676.83
16	BASIC AND DILUTED EPS (NOT ANNUALISED)	0.45	2.07	0.63	6.36	5.82	8.00	5.81

STATEMENT OF ASSETS AND LIABILITIES AS AT 31st March, 2016

(Rs in Lacs)

	Particulars	STANDALONE		CONSOLIDATED	
		Mar-16	Mar-15	Mar-16	Mar-15
I.	**EQUITY AND LIABILITIES**				
1	**SHAREHOLDERS' FUNDS :**				
	(i) Share Capital	1,031.47	1,031.47	1,031.47	1,031.47
	(ii) Reserves and Surplus	42,175.96	35,787.14	40,230.77	32,676.83
	Sub-total - Shareholders' funds	**43,207.43**	**36,818.61**	**41,262.24**	**33,708.30**
2	**Minority Interest**			**3,309.57**	**1,489.18**
3	**Non- Current liabilities**				
	(i) Long term Borrowings	1,184.07	3,020.95	3,824.27	5,725.81
	(ii) Deferred tax liabilities (Net)	827.58	715.30	948.86	885.94
	(iii) Long term provisions	166.84	139.85	181.43	139.85
	Sub-total - Non-current liabilities	**2,178.49**	**3,876.10**	**4,954.56**	**6,751.60**
4	**Current liabilities**				
	(i) Short term Borrowings	4,994.61	2,837.62	6,212.38	6,104.21
	(ii) Trade payables	3,506.15	5,046.72	10,848.57	8,033.39
	(iii) Other current liabilities	2,909.99	3,913.46	5,275.63	7,030.05
	(iv) Short term provisions	1,671.81	3,007.62	4,315.23	3,100.09
	Sub-total -current liabilities	**13,082.56**	**14,805.42**	**26,651.81**	**24,267.74**
	Total……	**58,468.48**	**55,500.13**	**76,178.18**	**66,216.82**
II.	**ASSETS**				
1	**Non-current assets**				
	(a) Fixed Assets	8,107.45	8,150.39	19,059.22	16,062.00
	(b) Goodwill on Consolidation	-	-	4,375.64	7,376.00
	(c) Non-current Investments	2,059.37	1,922.63	11.02	1.01
	(d) Long term loans and advances	11,044.68	10,135.08	5,677.48	1,026.79
	(e) Other non current assets	-	43.26	-	43.26
	Sub-total - Non-current assets	**21,211.50**	**20,251.36**	**29,123.36**	**24,509.06**
2	**Current assets**				
	(a) Inventories	2,194.92	2,251.83	3,867.30	3,370.00
	(b) Trade receivables	25,057.83	21,061.21	30,093.29	24,746.94
	(c) Cash and Bank balances	5,689.76	4,736.77	7,817.66	5,728.93
	(d) Short term loans and advances	3,215.96	6,133.62	5,041.92	7,470.88
	(e) Other current assets	1,098.51	1,065.34	234.65	391.01
	Sub-total - Current assets	**37,256.98**	**35,248.77**	**47,054.82**	**41,707.76**
	Total……	**58,468.48**	**55,500.13**	**76,178.18**	**66,216.82**

NOTES:-

1.THE ABOVE AUDITED FINANCIAL RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON MAY 24, 2016

2.THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2016 & 2015 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR AND THE YEAR TO DATE PUBLISHED RESULTS FOR THE NINE MONTHS ENDED DECEMBER 31, 2015 & 2014

3.THE CONSOLIDATED RESULTS INCLUDES THE AUDITED FINANCIAL RESULTS OF PARENT COMPANY, THE SUBSIDIARIES NAMELY BLISS GVS INTERNATIONAL PTE LTD, BLISS INDASI LIFE SCIENCES PVT LTD, BLISS GVS CLINIC HEALTHCARE PTE LTD, KREMOINT PHARMA PVT. LTD., LIFEON LABS PVT LTD, ASTERISK LIFESCIENCES LTD AND SHREE SALES PACK PVT LTD

4. THE TAX EXPENSE FOR THE YEAR ENDED MARCH 31,2016 IS NET OF A REFUND OF RS. 217.33 LACS PERTAINING TO PRIOR YEARS, IN RESPECT OF WHICH A FAVOURABLE ORDER WAS RECEIVED BY THE COMPANY DURING THE QUARTER.

5.THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.

GEOGRAPHICAL SEGMENT DISCLOSURE:-

I) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED MARCH 31, 2016 - RS. 375.83 LACS AND RS. 5716.44 LACS

II) REVENUES WITHIN AND OUTSIDE INDIA FOR THE YEAR ENDED MARCH 31, 2016- RS. 2045.73 LACS AND RS. 29923.51 LACS RESPECTIVELY

6. THE BOARD HAS RECOMMENDED A DIVIDEND OF 50% i.e Rs. 0.50 PER EQUITY SHARE FOR THE YEAR ENDED 31ST MARCH 2016, WHICH IS SUBJECT TO SHAREHOLDERS' APPROVAL AT THE END OF THE ENSUING ANNUAL GENERAL MEETING.

7.FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.

PLACE : MUMBAI
DATE : 24th May 2016

FOR BLISS GVS PHARMA LTD
SD/-
S.N. KAMATH
MANAGING DIRECTOR

B. K. KHARE & CO.
CHARTERED ACCOUNTANTS

T + 91 022 22000607/7318/6360
+ 91 022 66315835/36
F + 91 022 2200 3476
E info@bkkhareco.com
706/708, Sharda Chambers New Marine Lines, Mumbai - 400 020, India

Auditor's Report on the Standalone Results of the Company for the quarter and year ended March 31, 2016 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of Bliss GVS Pharma Limited

1. (a) We have audited the standalone financial results of Bliss GVS Pharma Limited ("the Company") for the quarter and the year ended March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The quarterly standalone financial results for the quarter ended March 31, 2016 are the derived figures between the audited figures for the year ended March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the end of the previous quarter of the current financial year, which were subjected to a limited review.

   (b) The standalone financial results for the quarter ended March 31, 2016 have been prepared on the basis of the interim standalone financial statements for the nine-month period ended December 31, 2015, the audited standalone financial statements for the year ended March 31, 2016, and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. The standalone interim financial statements for the nine-month period ended December 31, 2015 and the audited standalone financial statements for the year ended March 31, 2016 have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 – "Interim Financial Reporting" and the accounting standards specified under Section 133 of the Companies Act, 2013, respectively, read with the relevant rules issued thereunder, and other accounting principles generally accepted in India.

   (c) Our responsibility is to express an opinion on these standalone financial results based on our review of such interim standalone financial statements and audit of the standalone financial statements as at and for the year ended March 31, 2016.

2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the financial results. An audit also includes assessing the accounting principles used and the significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Pune
T + 91 020 6060
+ 91 020 25666932/32926341
E bkkpune@bkkhareco.com
Hotel Swaroop, 4th Floor,
Lane No.10, Prabhat Road,
Erandwane, Pune - 411 004, India

Bengaluru
T + 91 80 41105357
E bkkbengaluru@bkkhareco.com
101, Money Chambers,
1st Floor, # 6 K. H. Road,
Shanthinagar,
Bengaluru - 560027, India

New Delhi
T + 91 011 4905 7624
E bkkdelhi@bkkhareco.com
A - 4, Westend,
Rao Tula Ram Marg,
New Delhi - 110021,
India

3. In our opinion and to the best of our information and according to the explanations given to us these quarterly and annual financial results for the quarter and year ended March 31, 2016:
   (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
   (ii) give a true and fair view of the net profit and other standalone financial information for the quarter as well as year ended March 31, 2016.

4. We draw attention to our reliance on management representation, in respect of the realisability of the Company's investment in and loan given to two of its subsidiaries (net of the amount realisable/receivable on disposal of a step down subsidiary) aggregating Rs. 8,432.44 lakhs.

   Our opinion is not modified in respect of this matter.

For B. K. Khare & Co.
Chartered Accountants
Firm's Registration Number 105102W

Himanshu Chapsey
Partner
Membership Number 105731

Mumbai, May 24, 2016

B. K. KHARE & CO.
CHARTERED ACCOUNTANTS

T + 91 022 22000607/7318/6360
+ 91 022 66315835/36
F + 91 022 2200 3476
E info@bkkhareco.com
706/708, Sharda Chambers New Marine Lines, Mumbai - 400 020, India

Auditor's Report on the Consolidated Results of the Company for the year ended March 31, 2016 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of Bliss GVS Pharma Limited

1. (a) We have audited the consolidated financial results of Bliss GVS Pharma Limited ("the Holding Company") and its subsidiary companies (the Holding Company and its subsidiary are hereinafter referred to as "the Group") for the year ended March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Consolidated Financial Results").

   (b) These consolidated financial results have been prepared from the consolidated financial statements of the Company as at and for the year ended March 31, 2016, and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are the responsibility of the Company's management and have been approved by the Board of Directors. The consolidated financial statements as at and for the year ended March 31, 2016 have been prepared in accordance with the accounting standards specified under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India.

   (c) Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated financial statements.

2. We conducted our audit in accordance with auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the consolidated financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

3. (a) We did not audit the financial statements of 7 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets (before consolidation adjustments) of Rs 25,343.89 lakhs as at March 31, 2016 as well as total revenue (before consolidation adjustments) of Rs 24,638.74 lakhs for the year then ended. These financial statements and other financial information have been audited by other auditors whose reports have been furnished to us by the management, and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and to the extent they have been derived from such financial statements is based solely on the report of such other auditors.

Pune
T + 91 020 30601005/6/7/8/9,
+ 91 020 25656932/32926341
E bkkpune@bkkhareco.com
Hotel Swaroop, 4th Floor,
Lane No.10, Prabhat Road,
Erandwane, Pune - 411 004, India

Bengaluru
T + 91 80 41105357
E bkkbengaluru@bkkhareco.com
101, Money Chambers,
1st Floor, # 6 K. H. Road,
Shanthinagar,
Bengaluru - 560027, India

New Delhi
T + 91 011 4905 7624
E bkkdelhi@bkkhareco.com
A - 4, Westend,
Rao Tula Ram Marg,
New Delhi - 110021,
India

(b) We did not audit the financial statements of 3 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets (before consolidation adjustments) of Rs 10,570.95 lakhs as at March 31, 2016 as well as total revenue (before consolidation adjustments) of Rs 835.31 lakhs for the year then ended. These financial statements and other financial information are unaudited and have been furnished to us by the management, and our opinion on the consolidated financial results, to the extent they have been derived from such financial statements is based solely on such unaudited financial statements / financial information. In our opinion, according to the information and explanations given to us by the management and in view of the fact that a substantial portion of the amounts referred to above eliminate on consolidation, these financial statements / financial information are not material to the consolidated financial results of the Group.

4. In our opinion and to the best of our information and according to the explanations given to us these consolidated financial results
   (i) include financial results of the following subsidiaries included in the consolidation:
      a. Bliss Indasi Lifescience Private Ltd
      b. Bliss GVS International Pte Ltd
      c. Bliss GVS Clinic Healthcare Pte Ltd
      d. Kremoint Pharma Private Ltd
      e. Lifeon Labs Private Limited
      f. Asterisk Lifesciences Limited
      g. Shree Sales Pack Private Limited
      h. Eipii Exports Private Limited
      i. Greenlife Bliss Healthcare Limited
      j. Bliss GVS Healthcare Limited
      k. Asterisk Lifesciences (GH) Limited
   (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
   (iii) give a true and fair view of the consolidated net profit and other financial information for the year ended March 31, 2016.

5. We draw attention to our reliance on the management representation that no provision is required for goodwill on consolidation arising in respect of its subsidiary aggregating Rs 3,549.05 lakhs as at March 31, 2016

   Our opinion is not modified in respect of this matter.

For B. K. Khare & Co.
Chartered Accountants
Firm's Registration Number 105102W

Himanshu Chapsey
Partner
Membership Number 105731
Mumbai, May 24, 2016

B. K. KHARE & CO. MUMBAI CHARTERED ACCOUNTANTS

BLISS GVS PHARMA LTD.

FORM A

(For Audit Report with unmodified opinion)

[Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

Date: 24th May, 2016

1)	Name of the Company	Bliss GVS Pharma Limited
2)	Annual financial Statements for the year ended	March 31, 2016 (Consolidated)
3)	Type of Observation	Unqualified report Emphasis of Matter: See Emphasis of Matter section of Audit Report on the Financial Results
4)	Frequency of Observation	Since 2015
5)	To be signed by-	
	Mr. S. N. Kamath Managing Director	BLISS GVS PHARMA LTD. MUMBAI
	Mr. Vipul B. Thakkar Chief Financial Officer	BLISS GVS PHARMA LTD. MUMBAI
	Mr. Himanshu Chapsey Auditor of the Company	B. K. KHARE & CO. CHARTERED ACCOUNTANTS MUMBAI
	Mr. Mayank Mehta Chairman of Audit Committee	BLISS GVS PHARMA LTD. MUMBAI

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

BLISS GVS PHARMA LTD.

FORM A

(For Audit Report with unmodified opinion)

[Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

Date: 24th May, 2016

1)	Name of the Company	Bliss GVS Pharma Limited
2)	Annual financial Statements for the year ended	March 31, 2016 (Standalone)
3)	Type of Observation	Unqualified report Emphasis of Matter: See Emphasis of Matter section of Audit Report on the Financial Results
4)	Frequency of Observation	Since 2015
5)	To be signed by-	
	Mr. S. N. Kamath Managing Director	
	Mr. Vipul B. Thakkar Chief Financial Officer	
	Mr. Himanshu Chapsey Auditor of the Company	
	Mr. Mayank Mehta Chairman of Audit Committee	

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com